Inhibikase Therapeutics, Inc. (40)
Browse by Contract Category
Contracts
-
2020 Equity Incentive Plan and forms of agreements thereunder
(Filed With SEC on December 4, 2020)
-
Amendment to Promissory Note by and between Inhibikase Therapeutics, Inc. and Flagship Consulting, Inc., dated October
(Filed With SEC on November 3, 2020)
-
Lease Agreement, dated June 5, 2020, by and between Inhibikase Therapeutics, Inc. and Regus Management Group, LLC
(Filed With SEC on July 23, 2020)
-
License Agreement, by and between Inhibikase Therapeutics, Inc. and Emory University, dated June 8, 2010
(Filed With SEC on July 23, 2020)
-
Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics, Inc. and Sphaera Pharma Pte. Ltd., dated February 29, 2012
(Filed With SEC on July 23, 2020)
-
2020 Equity Incentive Plan and forms of agreements thereunder
(Filed With SEC on November 3, 2020)
-
Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020
(Filed With SEC on September 15, 2020)
-
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2019
(Filed With SEC on September 15, 2020)
-
Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020
(Filed With SEC on September 15, 2020)
-
Warrant, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 25, 2020
(Filed With SEC on September 15, 2020)
-
Amended and Restated Second Convertible Revolving Demand Promissory 2020 Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated August 31, 2020
(Filed With SEC on September 15, 2020)
-
Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated February 5, 2020
(Filed With SEC on September 15, 2020)
-
Letter Agreement to Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, dated September 11, 2020
(Filed With SEC on September 15, 2020)
-
Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting Inc., dated April 3, 2018
(Filed With SEC on September 15, 2020)
-
2020 Equity Incentive Plan and forms of agreements thereunder
(Filed With SEC on September 15, 2020)
-
Consulting Agreement, by and between Inhibikase Therapeutics Inc. and Flagship Consulting, Inc., dated April 1, 2018
(Filed With SEC on September 15, 2020)
-
Form of Inhibikase Therapeutics, Inc. Subscription Agreement
(Filed With SEC on July 23, 2020)
-
Form of Consulting Agreement
(Filed With SEC on July 23, 2020)
-
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated June 15, 2018
(Filed With SEC on July 23, 2020)
-
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated August 31, 2018
(Filed With SEC on July 23, 2020)
-
Side Letter to Subscription Agreement of Joseph Ventures Allium, LLC, dated July 19, 2018
(Filed With SEC on July 23, 2020)
-
Form of Underwriting Agreement, including the Form of Lock-Up Agreement
(Filed With SEC on July 23, 2020)
-
Specimen common stock Certificate of the Registrant
(Filed With SEC on July 23, 2020)
-
Second Convertible Revolving Demand Promissory 2019 Note, issued by Inhibikase Therapeutics, Inc. to Joseph Frattaroli, dated December 31, 2019
(Filed With SEC on July 23, 2020)
-
Form of Warrant to purchase common stock of the Registrant, issued to each of the investors named in Schedule A thereto
(Filed With SEC on July 23, 2020)
-
Warrant dated October 5, 2018, issued by Inhibikase Therapeutics, Inc. to Kubera North America, Inc
(Filed With SEC on July 23, 2020)
-
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated January 1, 2020
(Filed With SEC on July 23, 2020)
-
Warrant, issued by Inhibikase Therapeutics, Inc. to Francis E. McDaniel, dated March 31, 2020
(Filed With SEC on July 23, 2020)
-
Form of Representatives Warrant
(Filed With SEC on July 23, 2020)
-
Form of Late IPO Warrant
(Filed With SEC on July 23, 2020)
-
Convertible Revolving Demand Promissory Note, issued by Inhibikase Therapeutics, Inc. to Flagship Consulting, Inc., dated April 3, 2018
(Filed With SEC on July 23, 2020)
-
Restated Agreement to Repay Individual Loan, by and between Inhibikase Therapeutics Inc. and Milton H. Werner, Ph.D., dated June 13, 2020
(Filed With SEC on July 23, 2020)
-
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Joseph Frattaroli, dated October 24, 2018
(Filed With SEC on July 23, 2020)
-
Fifth Restatement and Amendment to Promissory Note, issued by Inhibikase Therapeutics, Inc. to McDaniel Law Firm, PC, dated June 30, 2020
(Filed With SEC on July 23, 2020)
-
First Amendment to Collaborative Research and Development Agreement, by and between Inhibikase Therapeutics Inc. and Sphaera Pharma Pte. Ltd., dated October 5, 2012
(Filed With SEC on July 23, 2020)
-
2011 Equity Incentive Plan and forms of agreements thereunder
(Filed With SEC on July 23, 2020)
-
2020 Equity Incentive Plan
(Filed With SEC on July 23, 2020)
-
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner, Ph.D, dated April 1, 2014
(Filed With SEC on July 23, 2020)
-
Employment Agreement, by and between Inhibikase Therapeutics, Inc. and Milton H. Werner Ph.D, to be in effect upon the completion of this offering
(Filed With SEC on July 23, 2020)
-
Form of Inhibikase Therapeutics, Inc. Directors and Officers Indemnification Agreement
(Filed With SEC on July 23, 2020)